Literature DB >> 21400045

Apolipoproteins and amyloid fibril formation in atherosclerosis.

Chai Lean Teoh1, Michael D W Griffin, Geoffrey J Howlett.   

Abstract

Amyloid fibrils arise from the aggregation of misfolded proteins into highly-ordered structures. The accumulation of these fibrils along with some non-fibrillar constituents within amyloid plaques is associated with the pathogenesis of several human degenerative diseases. A number of plasma apolipoproteins, including apolipoprotein (apo) A-I, apoA-II, apoC-II and apoE are implicated in amyloid formation or influence amyloid formation by other proteins. We review present knowledge of amyloid formation by apolipoproteins in disease, with particular focus on atherosclerosis. Further insights into the molecular mechanisms underlying their amyloidogenic propensity are obtained from in vitro studies which describe factors affecting apolipoprotein amyloid fibril formation and interactions. Additionally, we outline the evidence that amyloid fibril formation by apolipoproteins might play a role in the development and progression of atherosclerosis, and highlight possible molecular mechanisms that could contribute to the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400045      PMCID: PMC4723368          DOI: 10.1007/s13238-011-1013-6

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  118 in total

Review 1.  Protein folding and misfolding.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 2.  Effects of mutation on the amyloidogenic propensity of apolipoprotein C-II(60-70) peptide.

Authors:  Nevena Todorova; Andrew Hung; Simon M Maaser; Michael D W Griffin; John Karas; Geoffrey J Howlett; Irene Yarovsky
Journal:  Phys Chem Chem Phys       Date:  2010-10-11       Impact factor: 3.676

3.  A specific apoprotein activator for lipoprotein lipase.

Authors:  J C LaRosa; R I Levy; P Herbert; S E Lux; D S Fredrickson
Journal:  Biochem Biophys Res Commun       Date:  1970-10-09       Impact factor: 3.575

4.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Authors:  M B Pepys; J Herbert; W L Hutchinson; G A Tennent; H J Lachmann; J R Gallimore; L B Lovat; T Bartfai; A Alanine; C Hertel; T Hoffmann; R Jakob-Roetne; R D Norcross; J A Kemp; K Yamamura; M Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; S Kolstoe; S P Wood; P N Hawkins
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

5.  Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants.

Authors:  B Permanne; C Perez; C Soto; B Frangione; T Wisniewski
Journal:  Biochem Biophys Res Commun       Date:  1997-11-26       Impact factor: 3.575

6.  Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100.

Authors:  V Chauhan; X Wang; T Ramsamy; R W Milne; D L Sparks
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

7.  Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I.

Authors:  Yuan Qi Wong; Katrina J Binger; Geoffrey J Howlett; Michael D W Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

8.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

9.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

Review 10.  Amyloidosis.

Authors:  Mark B Pepys
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

View more
  28 in total

1.  Impact of self-association on function of apolipoprotein A-I.

Authors:  Shobini Jayaraman; Sumiko Abe-Dohmae; Shinji Yokoyama; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

Review 2.  Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Authors:  Melanie A Jackson; Nicholas Caputo; Jessica R Castle; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

3.  Conformational and aggregation properties of the 1-93 fragment of apolipoprotein A-I.

Authors:  Jitka Petrlova; Arnab Bhattacherjee; Wouter Boomsma; Stefan Wallin; Jens O Lagerstedt; Anders Irbäck
Journal:  Protein Sci       Date:  2014-08-23       Impact factor: 6.725

4.  Hot spots in apolipoprotein A-II misfolding and amyloidosis in mice and men.

Authors:  Olga Gursky
Journal:  FEBS Lett       Date:  2014-02-20       Impact factor: 4.124

5.  Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.

Authors:  Anita D'Souza; Jason D Theis; Julie A Vrana; Ahmet Dogan
Journal:  Amyloid       Date:  2014-01-22       Impact factor: 7.141

6.  Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.

Authors:  Adam J Loavenbruck; Vinay Chaudhry; Steven R Zeldenrust; Robert J Spinner; Jason D Theis; Christopher J Klein
Journal:  Muscle Nerve       Date:  2012-11       Impact factor: 3.217

Review 7.  Structural stability and functional remodeling of high-density lipoproteins.

Authors:  Olga Gursky
Journal:  FEBS Lett       Date:  2015-03-05       Impact factor: 4.124

Review 8.  Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights.

Authors:  Madhurima Das; Olga Gursky
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

9.  Heavy and light chain (AHL)-type cardiac amyloidosis: first histopathologic-proven case illustrating involvement of the heart.

Authors:  Miroslav Sekulic; Simona Pichler Sekulic; Astrid Weins
Journal:  Virchows Arch       Date:  2020-05-09       Impact factor: 4.064

10.  Apolipoprotein C-II Adopts Distinct Structures in Complex with Micellar and Submicellar Forms of the Amyloid-Inhibiting Lipid-Mimetic Dodecylphosphocholine.

Authors:  Timothy M Ryan; Michael D W Griffin; Duncan J McGillivray; Robert B Knott; Kathleen Wood; Colin L Masters; Nigel Kirby; Cyril C Curtain
Journal:  Biophys J       Date:  2016-01-05       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.